(Q38042090)

27 August 2017

U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma (English)

1 reference

27 August 2017

4

1 reference

27 August 2017

J J Scarisbrick

1

1 reference

27 August 2017

S Morris

2

1 reference

27 August 2017

R Azurdia

3

1 reference

27 August 2017

E Parry

5

1 reference

27 August 2017

R Graham-Brown

6

1 reference

27 August 2017

R Cowan

7

1 reference

27 August 2017

E Gallop-Evans

8

1 reference

27 August 2017

R Wachsmuth

9

1 reference

27 August 2017

M Eagle

10

1 reference

27 August 2017

A S Wierzbicki

11

1 reference

27 August 2017

H Soran

12

1 reference

27 August 2017

S Whittaker

13

1 reference

27 August 2017

E M Wain

14

1 reference

27 August 2017

language of work or name

English

0 references

publication date

3 December 2012

1 reference

British Journal of Dermatology

27 August 2017

1 reference

27 August 2017

168

1 reference

27 August 2017

1

1 reference

27 August 2017

192-200

1 reference

Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma

27 August 2017

1 reference

Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas.

21 January 2018

1 reference

Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

Bexarotene therapy for mycosis fungoides and Sézary syndrome.

21 January 2018

1 reference

Optimizing bexarotene therapy for cutaneous T-cell lymphoma

21 January 2018

1 reference

The optimal use of bexarotene in cutaneous T-cell lymphoma

21 January 2018

1 reference

Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion

21 January 2018

1 reference

Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms

21 January 2018

1 reference

JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice

21 January 2018

1 reference

Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.

21 January 2018

1 reference

Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma

21 January 2018

1 reference

Bexarotene-induced hypothyroidism: bexarotene stimulates the peripheral metabolism of thyroid hormones.

21 January 2018

1 reference

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

Statin-fibrate combination: therapy for hyperlipidemia: a review

21 January 2018

1 reference

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin

21 January 2018

1 reference

Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).

21 January 2018

1 reference

Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids.

21 January 2018

1 reference

Niacin: the only vitamin that reduces cardiovascular events

21 January 2018

1 reference

Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia

21 January 2018

1 reference

The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel

21 January 2018

1 reference

Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia

21 January 2018

1 reference

The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations

21 January 2018

1 reference

Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.

21 January 2018

1 reference

Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists

21 January 2018

1 reference

Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein

21 January 2018

1 reference

Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus

21 January 2018

1 reference

21 January 2018

1 reference

Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJD.12042

1 reference

27 August 2017

1 reference